FIELD: medicine; pharmaceuticals.
SUBSTANCE: group of inventions concerns the pharmaceutical composition for oral administration, which comprises the parathyroid hormone (PTH), the protease inhibitor, the absorption enhancer that is selected from the group consisting of N-(8-[2-hydroxybenzoyl]amino)caprylate, N-(10-[2-hydroxybenzoyl]amino)decanoate, the salt of N-(8-[2-hydroxybenzoyl]amino)caprylate, the salt of N-(10-[2-hydroxybenzoyl]amino)decanoate and the combinations of these compounds. Method for oral administration of PTH in the composition is also stated.
EFFECT: group of inventions provides for the increased absorption of PTH in case of oral administration.
10 cl, 5 ex, 2 dwg
| Title | Year | Author | Number |
|---|---|---|---|
| METHODS AND COMPOSITIONS FOR ORAL PROTEIN ADMINISTRATION | 2009 |
|
RU2494755C2 |
| METHODS AND COMPOSITIONS FOR ORAL ADMINISTRATION OF PROTEINS | 2009 |
|
RU2504373C2 |
| COMPOSITIONS AND METHODS FOR ORAL ADMINISTRATION OF EXENATIDE | 2009 |
|
RU2566063C2 |
| MIMETIC CALCITONIN FOR TREATING DISEASES AND DISORDERS | 2014 |
|
RU2689551C1 |
| APPLICATION OF CALCITONIN FOR TREATING RHEUMATOID ARTHRITIS | 2006 |
|
RU2453330C2 |
| CALCITONIN USED AT OSTEOARTHRITIS | 2004 |
|
RU2368390C2 |
| METHODS FOR PREPARING ACYCLOVIR FORMULATION | 2005 |
|
RU2406504C2 |
| SOLID COMPOSITIONS FOR ORAL ADMINISTRATION | 2018 |
|
RU2777206C2 |
| TREATING DIABETES AND METABOLIC SYNDROME | 2010 |
|
RU2537181C2 |
| COMPOSITIONS FOR DRUG INTRODUCTION | 2009 |
|
RU2554814C2 |
